Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer?

Lancet Oncol. 2020 Jun;21(6):741-743. doi: 10.1016/S1470-2045(20)30208-4. Epub 2020 May 18.

Authors

Yukiya Narita¹, Shigenori Kadowaki¹, Kei Muro²

Affiliations

¹ Department Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 4648681, Japan.
² Department Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 4648681, Japan. Electronic address: kmuro@aichi-cc.jp.

PMID: 32437663
DOI: 10.1016/S1470-2045(20)30208-4

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized*
Esophagogastric Junction
Humans
Stomach Neoplasms*
Trastuzumab

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab
Trastuzumab